Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness

Recruiting N/A Interventional Study
Prostate Cancer (Adenocarcinoma) Low and Intermediate Risk Prostate Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 85
Sex
Male
Study type
Interventional
Purpose
Treatment
Participants needed
7 (estimated)
Sponsor
University Health Network, Toronto · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk prostate cancer (PCa) to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation Therapy) for their disease.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Men 40-80 years of age. * Histologically-proven intermediate-risk PCa (Gleason score 7, primary grade ≤ 4). * PCa clinical stage T1c or T2. * MRI/MicroUS site suspicious for cancer or cancer mapped to one prostate lobe. * Maximum dimension of MRI/MicroUS visible tumour ≤15mm. …
Contacts

Kateri Corr

416-946-4501

kateri.corr@uhn.ca

CONTACT

Sangeet Ghai, MD

416-340-4656

sangeet.ghai@uhn.ca

CONTACT